Review article: the therapeutic potential of 5-HT3receptor antagonists in the treatment of irritable bowel syndrome
| Autor: | Nick M. Clayton, K. Kozlowski, C. Bountra, P.P.A. Humphrey |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Abdominal pain
Hepatology biology business.industry medicine.drug_class Gastroenterology Pharmacology medicine.disease Receptor antagonist 5-HT3 receptor Blockade nervous system Alosetron medicine biology.protein Pharmacology (medical) medicine.symptom Serotonin Antagonists Receptor business Irritable bowel syndrome medicine.drug |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 13:31-38 |
| ISSN: | 0269-2813 |
| DOI: | 10.1046/j.1365-2036.1999.00003.x-i2 |
| Popis: | There is evidence from studies, in both animals and humans, that 5-HT3 receptor blockade has potential value in the treatment of irritable bowel syndrome, particularly in those patients with diarrhoea-predominant bowel habits. New findings suggest that 5-HT3 receptors exist on gut afferent neurones and that their activation by locally released 5-HT leads to visceral nociceptive stimulation, in addition to increased neuronally-mediated motor and secretory activity. If this concept is validated, it will provide a rationale for the use of 5-HT3 receptor antagonists in patients with increased gut motility, reduced fluid absorption and low nociceptive thresholds leading to abdominal pain. Alosetron is a highly selective, potent 5-HT3 receptor antagonist which is well absorbed with a long pharmacodynamic half-life. Its ability to provide long-lasting blockade of 5-HT3 receptors throughout the body make it an ideal candidate within its class to evaluate the clinical hypothesis that sustained and ubiquitous 5-HT3 receptor blockade is of value in the treatment of IBS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|